Design Therapeutics Valuation
| DSGN Stock | USD 4.65 0.01 0.22% |
At this time, the firm appears to be undervalued. Design Therapeutics shows a prevailing Real Value of $5.61 per share. The current price of the firm is $4.65. Our model computes the value of Design Therapeutics from reviewing the firm fundamentals such as Shares Owned By Insiders of 36.35 %, current valuation of 20.8 M, and Shares Owned By Institutions of 59.33 % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Design Therapeutics' valuation include:
Price Book 1.0903 | Enterprise Value | Enterprise Value Ebitda (0.84) | Price Sales 22.6 K | Enterprise Value Revenue 11 K |
Undervalued
Today
Please note that Design Therapeutics' price fluctuation is unstable at this time. Calculation of the real value of Design Therapeutics is based on 3 months time horizon. Increasing Design Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Design Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Design Stock. However, Design Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.65 | Real 5.61 | Target 7.0 | Hype 4.66 | Naive 4.38 |
The intrinsic value of Design Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Design Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Design Therapeutics helps investors to forecast how Design stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Design Therapeutics more accurately as focusing exclusively on Design Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Design Therapeutics' intrinsic value based on its ongoing forecasts of Design Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Design Therapeutics' closest peers.
Design Therapeutics Cash |
|
Design Valuation Trend
Knowing Design Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Design Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Design Therapeutics Total Value Analysis
Design Therapeutics is currently forecasted to have valuation of 20.8 M with market capitalization of 263.95 M, debt of 1.53 M, and cash on hands of 359.38 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Design Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
20.8 M | 263.95 M | 1.53 M | 359.38 M |
Design Therapeutics Asset Utilization
One of the ways to look at asset utilization of Design is to check how much profit was generated for every dollar of assets it reports. Design Therapeutics shows a negative utilization of assets of -0.14 percent, losing $0.001439 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Design Therapeutics shows how discouraging it operates for each dollar spent on its assets.Design Therapeutics Ownership Allocation
Design Therapeutics holds a total of 56.76 Million outstanding shares. Over half of Design Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Design Therapeutics Profitability Analysis
Net Loss for the year was (49.59 M) with loss before overhead, payroll, taxes, and interest of (44.35 M).About Design Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Design Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Design Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Design Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Design Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Design Therapeutics. We calculate exposure to Design Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Design Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -483.3 K | -459.1 K | |
| Pretax Profit Margin | -42.1 K | -44.2 K | |
| Operating Profit Margin | -42.4 K | -44.5 K | |
| Net Loss | -42.1 K | -44.2 K | |
| Gross Profit Margin | (24.29) | (25.51) |
Design Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 56.6 M |
Design Therapeutics Current Valuation Indicators
Design Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Design Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Design Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Design Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Design Therapeutics' worth.When determining whether Design Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Design Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Design Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Design Therapeutics Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Design Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.